Canurta Journal

In November, Canurta CEO Akeem Gardner joined world leaders at the Hevolution Foundation’s Global Healthspan Summit in Riyadh and presented at Bio-Europe and OBIO’s Investment Summit. The company also progressed R&D with a sublingual strip formulation, ALS toxicity trials, and new bioinformatics applications for ALS and ARDS.

Canurta partners with International Speciality Supply to commercialize Activated Hemp Seed Powder in Q1 2024. The company also released new research on cannabis-derived stilbenes, introduced its automated compliance platform FilingFlow, and completed key R&D milestones ahead of Bio-Europe 2023.

In September, Canurta raised over $4,500 for ALS Canada and placed second in the Pull to End ALS challenge. The company announced a validated global standard for detecting cannflavins in hemp extracts, advanced commercial production, and concluded the first phase of its novel molecule generation project.

In August, Canurta progressed toward commercial readiness through a key production partnership with FSOil, continued fundraising for ALS Canada, and released a new episode of the Canurta Day video series. The team also marked R&D milestones in respiratory therapeutics and QSAR modeling, and celebrated contributions from University of Guelph MBIOT summer students.

Canurta’s June was marked by a successful investor pitch day, new research presentations, and strengthened efforts in ALS and cancer research. Highlights include funding for preclinical work on breast cancer, promising virology and inflammation results from cannflavin testing, and continued development of Canurta’s internal molecule database and blockchain platform.

In May, Canurta presented glioblastoma-focused research at CannMed23, sponsored and spoke at the CSPS Symposium, and celebrated team member Samantha Palloo’s recognition with a national award. Operational progress in Grimsby and new biotech collaborations with University of Guelph continue to support Canurta’s clinical and biosynthesis goals.

In April, Canurta shared its clinical pipeline at ACT Canada and connected with global investors at the Bloom Burton Healthcare Conference. The company also progressed pharmacokinetic trials, advanced IP strategy through NRC IRAP support, and opened eight summer positions to foster emerging talent.

Canurta’s Annual General Meeting outlined key 2023 priorities including preclinical advancement, financing preparation, and asset commercialization. The company also received new NRC IRAP funding for respiratory disease research, was recognized for leadership by The Peak, and marked significant milestones in R&D, bioinformatics, and IT infrastructure.

Canurta has officially established its operations in Grimsby, Ontario, received registration for its trademark, and presented its glioblastoma research at BE-STEMM 2023. The company will also present at CannMed '23, continuing to showcase the therapeutic potential of cannabis-derived flavonoids.

Canurta’s R&D team has developed a proprietary flash chromatography method for isolating novel hemp polyphenols and is deploying immobilized-enzyme reactors to produce purified therapeutic compounds. The company also welcomed three new bioinformatics scientists through NRC IRAP funding to support its computer-aided drug design pipeline.

Canurta’s CEO presented key research abstracts on glioblastoma and hemp-derived APIs at Canna Pharma 2022 in San Diego. The company also joined the CELS Valley Ready Program, building its presence in the Silicon Valley life sciences ecosystem.

Canurta presented novel glioblastoma research at the Polyphenols Applications World Congress, announced upcoming Canna Pharma participation, and shared its acceptance into both the adMare Executive Institute and AC: Studio programs, further expanding its national leadership in biotechnology.

Canurta presented its glioblastoma research at the Polyphenols Applications World Congress and connected with key partners at the Canadian Health Food Association Tradeshow. The company also celebrated the achievements of its summer research students.

Canurta will present groundbreaking research on cannabis-derived flavonoids for glioblastoma at the 15th Polyphenols Applications World Congress. The company also prepares to showcase its Activated Hemp Seed Powder at Canada’s leading natural health tradeshow.

Canurta highlights progress in biosynthetic research, strategic R&D partnerships, and production scale-up efforts following its presentation at the Canada SynBio Conference.

Canurta is pleased to announce the addition of University of Guelph researchers Dr. Kelly Boddington, Ph.D. and Dr. Eric Soubeyrand, Ph.D. to the team to scale up Canurta’s ability to biosynthetically produce rare hemp polyphenols.

Canurta is pleased to announce that Ethan Russo, MD, the preeminent global medical Cannabis expert, has joined the executive team as Senior Medical Advisor and will provide an exclusive license to related IP through his company CReDO Science, LLC.